Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery.

Clicks: 260
ID: 52509
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #43 of 62 articles by views in annals of internal medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Uncertainty remains about the effects of aspirin in patients with prior percutaneous coronary intervention (PCI) having noncardiac surgery.To evaluate benefits and harms of perioperative aspirin in patients with prior PCI.Nonprespecified subgroup analysis of a multicenter factorial trial. Computerized Internet randomization was done between 2010 and 2013. Patients, clinicians, data collectors, and outcome adjudicators were blinded to treatment assignment. (ClinicalTrials.gov: NCT01082874).135 centers in 23 countries.Adults aged 45 years or older who had or were at risk for atherosclerotic disease and were having noncardiac surgery. Exclusions were placement of a bare-metal stent within 6 weeks, placement of a drug-eluting stent within 1 year, or receipt of nonstudy aspirin within 72 hours before surgery.Aspirin therapy (overall trial, n = 4998; subgroup, n = 234) or placebo (overall trial, n = 5012; subgroup, n = 236) initiated within 4 hours before surgery and continued throughout the perioperative period. Of the 470 subgroup patients, 99.9% completed follow-up.The 30-day primary outcome was death or nonfatal myocardial infarction; bleeding was a secondary outcome.In patients with prior PCI, aspirin reduced the risk for the primary outcome (absolute risk reduction, 5.5% [95% CI, 0.4% to 10.5%]; hazard ratio [HR], 0.50 [CI, 0.26 to 0.95]; P for interaction = 0.036) and for myocardial infarction (absolute risk reduction, 5.9% [CI, 1.0% to 10.8%]; HR, 0.44 [CI, 0.22 to 0.87]; P for interaction = 0.021). The effect on the composite of major and life-threatening bleeding in patients with prior PCI was uncertain (absolute risk increase, 1.3% [CI, -2.6% to 5.2%]). In the overall population, aspirin increased the risk for major bleeding (absolute risk increase, 0.8% [CI, 0.1% to 1.6%]; HR, 1.22 [CI, 1.01 to 1.48]; P for interaction = 0.50).Nonprespecified subgroup analysis with small sample.Perioperative aspirin may be more likely to benefit rather than harm patients with prior PCI.Canadian Institutes of Health Research.
Reference Key
graham2018aspirinannals Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Graham, Michelle M;Sessler, Daniel I;Parlow, Joel L;Biccard, Bruce M;Guyatt, Gordon;Leslie, Kate;Chan, Matthew T V;Meyhoff, Christian S;Xavier, Denis;Sigamani, Alben;Kumar, Priya A;Mrkobrada, Marko;Cook, Deborah J;Tandon, Vikas;Alvarez-Garcia, Jesus;Villar, Juan Carlos;Painter, Thomas W;Landoni, Giovanni;Fleischmann, Edith;Lamy, Andre;Whitlock, Richard;Le Manach, Yannick;Aphang-Lam, Meylin;Cata, Juan P;Gao, Peggy;Terblanche, Nicolaas C S;Ramana, Pamidimukkala V;Jamieson, Kim A;Bessissow, Amal;Mendoza, Gabriela R;Ramirez, Silvia;Diemunsch, Pierre A;Yusuf, Salim;Devereaux, P J;
Journal annals of internal medicine
Year 2018
DOI
10.7326/M17-2341
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.